Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease. A novel pre-clinical model expressing an enhanced version ...
Spur Therapeutics today announced positive feedback from its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), supporting its planned Phase 3 trial for FLT201, an ...